[go: up one dir, main page]

IS7859A - Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra - Google Patents

Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra

Info

Publication number
IS7859A
IS7859A IS7859A IS7859A IS7859A IS 7859 A IS7859 A IS 7859A IS 7859 A IS7859 A IS 7859A IS 7859 A IS7859 A IS 7859A IS 7859 A IS7859 A IS 7859A
Authority
IS
Iceland
Prior art keywords
methods
pharmaceutical compositions
protein kinase
inhibit protein
indazole compounds
Prior art date
Application number
IS7859A
Other languages
English (en)
Inventor
John Borchardt Allen
Steven Kania Robert
Louise Palmer Cynthia
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS7859A publication Critical patent/IS7859A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7859A 2002-12-19 2005-05-23 Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra IS7859A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43490202P 2002-12-19 2002-12-19
PCT/IB2003/005854 WO2004056806A1 (en) 2002-12-19 2003-12-08 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases

Publications (1)

Publication Number Publication Date
IS7859A true IS7859A (is) 2005-05-23

Family

ID=32682122

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7859A IS7859A (is) 2002-12-19 2005-05-23 Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra

Country Status (37)

Country Link
US (2) US7053107B2 (is)
EP (1) EP1585743B1 (is)
JP (1) JP3814285B2 (is)
KR (1) KR100730267B1 (is)
CN (1) CN1747950A (is)
AP (1) AP2005003341A0 (is)
AR (1) AR042510A1 (is)
AT (1) ATE362928T1 (is)
AU (1) AU2003286321A1 (is)
BR (1) BR0317548A (is)
CA (1) CA2510850A1 (is)
CO (1) CO5580767A2 (is)
CR (1) CR7882A (is)
DE (1) DE60314013T2 (is)
DK (1) DK1585743T3 (is)
EA (1) EA008501B1 (is)
EC (1) ECSP055858A (is)
GT (1) GT200300294A (is)
HR (1) HRP20050559A2 (is)
IS (1) IS7859A (is)
MA (1) MA27570A1 (is)
MX (1) MXPA05006676A (is)
NL (1) NL1025073C2 (is)
NO (1) NO20053486L (is)
NZ (1) NZ540340A (is)
OA (1) OA12977A (is)
PA (1) PA8592901A1 (is)
PE (1) PE20041006A1 (is)
PL (1) PL377713A1 (is)
PT (1) PT1585743E (is)
RS (1) RS20050430A (is)
SI (1) SI1585743T1 (is)
TN (1) TNSN05164A1 (is)
TW (1) TW200424193A (is)
UY (1) UY28130A1 (is)
WO (1) WO2004056806A1 (is)
ZA (1) ZA200504339B (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
JPWO2005094823A1 (ja) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006048745A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Methods for preparing indazole compounds
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
WO2007091107A1 (en) * 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
JPWO2008020606A1 (ja) * 2006-08-16 2010-01-07 協和発酵キリン株式会社 血管新生阻害剤
CA2688670A1 (en) * 2007-04-19 2008-10-30 Leo Pharma A/S Src family kinase inhibitors
RU2494089C2 (ru) 2007-04-20 2013-09-27 Акьюсела Инк. Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
WO2010022725A1 (en) 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
WO2011044157A1 (en) * 2009-10-06 2011-04-14 Biogen Idec Ma Inc. Heterocyclic compounds useful as pdk1 inhibitors
CN103804349A (zh) * 2012-11-01 2014-05-21 杨子娇 一类治疗青光眼的化合物及其用途
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CA2942888C (en) * 2014-03-31 2021-09-07 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
CN104744338A (zh) * 2015-03-31 2015-07-01 天津维智精细化工有限公司 一种6-氯羟吲哚的合成方法
WO2017024968A1 (zh) * 2015-08-07 2017-02-16 南京明德新药研发股份有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
CN109942544B (zh) * 2017-12-21 2021-06-11 中国科学院合肥物质科学研究院 一类新型吲唑类衍生物激酶抑制剂
JP2025528048A (ja) * 2022-08-08 2025-08-26 蘇州必揚医薬科技有限公司 プロテインチロシンキナーゼ阻害剤およびその医療上の使用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE217315T1 (de) 1996-07-18 2002-05-15 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
BR9714266A (pt) 1997-01-06 2000-04-18 Pfizer Derivados de sulfona cìclicos.
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
US6658447B2 (en) * 1997-07-08 2003-12-02 Intel Corporation Priority based simultaneous multi-threading
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
WO2000012498A1 (en) 1998-08-27 2000-03-09 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
HUP0103228A3 (en) 1998-08-27 2003-01-28 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents and pharmaceutical compositions containing them
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000038719A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1340051A (zh) 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
JP2001121829A (ja) * 1999-10-26 2001-05-08 Sony Chem Corp 情報記録用シート
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
TR200400342T4 (tr) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer

Also Published As

Publication number Publication date
HRP20050559A2 (en) 2006-02-28
CN1747950A (zh) 2006-03-15
DK1585743T3 (da) 2007-09-17
JP3814285B2 (ja) 2006-08-23
EP1585743B1 (en) 2007-05-23
UY28130A1 (es) 2004-07-30
AR042510A1 (es) 2005-06-22
CO5580767A2 (es) 2005-11-30
TW200424193A (en) 2004-11-16
ATE362928T1 (de) 2007-06-15
BR0317548A (pt) 2005-11-22
MXPA05006676A (es) 2005-08-16
PT1585743E (pt) 2007-07-12
AP2005003341A0 (en) 2005-06-30
MA27570A1 (fr) 2005-10-03
PA8592901A1 (es) 2005-02-04
KR20050084439A (ko) 2005-08-26
OA12977A (en) 2006-10-13
US20060160858A1 (en) 2006-07-20
GT200300294A (es) 2004-07-27
AU2003286321A1 (en) 2004-07-14
TNSN05164A1 (fr) 2007-05-14
ZA200504339B (en) 2006-07-26
NZ540340A (en) 2007-07-27
NO20053486L (no) 2005-07-18
ECSP055858A (es) 2005-09-20
US7053107B2 (en) 2006-05-30
PE20041006A1 (es) 2004-12-24
CR7882A (es) 2005-08-05
DE60314013D1 (de) 2007-07-05
US20040192735A1 (en) 2004-09-30
WO2004056806A1 (en) 2004-07-08
RS20050430A (sr) 2007-08-03
PL377713A1 (pl) 2006-02-06
NL1025073C2 (nl) 2005-02-01
KR100730267B1 (ko) 2007-06-20
EP1585743A1 (en) 2005-10-19
NL1025073A1 (nl) 2004-06-22
SI1585743T1 (sl) 2007-08-31
CA2510850A1 (en) 2004-07-08
EA200500811A1 (ru) 2005-12-29
EA008501B1 (ru) 2007-06-29
DE60314013T2 (de) 2008-01-17
JP2006515589A (ja) 2006-06-01

Similar Documents

Publication Publication Date Title
IS7859A (is) Indasól efnasambönd og lyfjasamsetningar til að hindra prótín kínasa og aðferðir við notkun þeirra
IS6207A (is) Indazol efnasambönd og lyfjafræðilegar blöndur til að hindra prótín kínasa og aðferð til að nota þau
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
DK1620429T3 (da) Nye heterocykliske forbindelser anvendelige til behandling af inflammatoriske og allergiske sygdomme, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
EP1673343A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
DK1673349T3 (da) Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
EP1670771A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
DK1354873T3 (da) Perindoaprilsalt og farmaceutiske sammensætninger indeholdende dette
DK1484970T3 (da) Benzamider og sammensætninger omfattende benzamider til anvendelse som fungicider
NO20041058L (no) Preparater og fremgangsmater relatert til nye benzodiazepinforbindelser og mal derav
EP1658290A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
EP1670780A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
NO20043295L (no) Faste salt-benzazepinforbindelser og deres anvendelse ved fremstilling av farmasoytiske forbindelser
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav